ReviewNature biotechnology2007
The growth and potential of human antiviral monoclonal antibody therapeutics.
Review in Nature biotechnology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
146 citing papers in PubMed, 279 citations in OpenAlex.
- Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.Antimicrobial agents and chemotherapy · 2016Trial
- Glycomic signatures on serum IgGs for prediction of postvaccination response.Scientific reports · 2015Trial
- Antiviral GHP-88310 blocks contact-mediated and airborne transmission in a ferret model of measles-like disease.Nature microbiology · 2026Article
- Thermal ablation plus HPV-specific IgY vaginal gel versus watchful waiting in women with histologically confirmed CIN1 and persistent HPV: a prospective observational cohort study.BMC women's health · 2026Observational
- Structure-Guided Engineering of High-Affinity Antibodies Against Zika Virus Using Deep Learning and Molecular Dynamics.Chemistry & biodiversity · 2026Article
- Direct airway delivery of a humanized anti-H7N9 neutralizing antibody broadly protects against divergent H7 influenza viruses in the mouse model.Journal of virology · 2025Article
- Mapping Antibody Epitopes by Solution NMR Spectroscopy: Practical Considerations.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Recent Advances in Immunological Landscape and Immunotherapeutic Agent of Nipah Virus Infection.Cell biochemistry and biophysics · 2024Review
- A broadly neutralizing human monoclonal antibody generated from transgenic mice immunized with HCMV particles limits virus infection and proliferation.Journal of virology · 2024Article
- AttABseq: an attention-based deep learning prediction method for antigen-antibody binding affinity changes based on protein sequences.Briefings in bioinformatics · 2024Article
- Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models.Nature communications · 2024Article
- A synergistic therapy against influenza virus A/H1N1/PR8 by a HA1 specific neutralizing single-domain VFrontiers in microbiology · 2024Article
- Single domain antibodies from camelids in the treatment of microbial infections.Frontiers in immunology · 2024Review
- Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.bioRxiv : the preprint server for biology · 2023Article
- Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies.Pharmaceutics · 2023Review
- Bioprocessing and the Production of Antiviral Biologics in the Prevention and Treatment of Viral Infectious Disease.Vaccines · 2023Review
- A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection.JHEP reports : innovation in hepatology · 2023Article
- Review
- A glycoengineered therapeutic anti-HBV antibody that allows increased HBsAg immunoclearance improves HBV suppressionFrontiers in pharmacology · 2023Article
- Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines.Current treatment options in infectious diseases · 2023Review
86 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Monoclonal antibodies (mAbs) have long provided powerful research tools for virologists to understand the mechanisms of virus entry into host cells and of antiviral immunity. Even so, commercial development of human (or humanized) mAbs for the prophylaxis, preemptive and acute treatment of viral infections has been slow. This is surprising, as new antibody discovery tools have increased the speed and precision with which potent neutralizing human antiviral mAbs can be identified. As longstanding barriers to antiviral mAb development, such as antigenic variability of circulating viral strains and the ability of viruses to undergo neutralization escape, are being overcome, deeper insight into the mechanisms of mAb action and engineering of effector functions are also improving the efficacy of antiviral mAbs. These successes, in both industrial and academic laboratories, coupled with ongoing changes in the biomedical and regulatory environments, herald an era when the commercial development of human antiviral mAb therapies will likely surge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.